diet drugs – Page 5 – Diet Business Watch

Weight Watchers Adds Compounded Meds

Oct. 8, 2024 WW announced the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions. The new offering, starting at $129, enhances the Company’s holistic weight management program, which includes behavioral and clinical solutions with support from board-certified clinicians, registered dietitians, and the global Weight Watchers community. This […]

Weight Watchers Adds Compounded Meds Read More »

Weight Loss Market’s Leaders Lost At Least $971 Million in 2023

News / John LaRosa

Sept. 24, 2024 Marketdata LLC, DietBusinessWatch.com’s parent), estimates that the top competitors in the U.S. weight loss market lost at least $971 million in revenues last year, due to the juggernaut of GLP-1 medications. This is a huge transfer of sales from commercial and retail weight loss programs and product segments to medical programs. Here’s

Weight Loss Market’s Leaders Lost At Least $971 Million in 2023 Read More »

Lindora Clinics Now Selling Franchises

News / John LaRosa

Sept. 19, 2024 Lindora Clinics, a long-time competitor in the medical weight loss market, has begun selling franchises. The firm has 31 sites, focused on the California market, but plans to expand nationally via franchising. Lindora franchisees’ gross revenue can vary, but the data provided in the brand’s 2024 FDD offers insight into potential earnings,

Lindora Clinics Now Selling Franchises Read More »

Study finds that 42% of online pharmacies selling semaglutide are illegal

News / John LaRosa

August 14, 2024 Nearly half of online pharmacies that sell semaglutide — the active ingredient in Ozempic and Wegovy — are doing so illegally, posing safety risks for consumers, according to a study published Aug. 2 in JAMA Network Open. Of the 317 online pharmacies included in the study, researchers found 42.27% were operating illegally, meaning

Study finds that 42% of online pharmacies selling semaglutide are illegal Read More »

23 and me To Enter The Weight Loss Market

News / John LaRosa

August 13, 2024 As reported by Fiercehealthcare.com today in an article… The genetic testing company 23andMe sees an opportunity to get in on the weight loss boom. The company, through its Lemonaid Health business, plans to launch a GLP-1 weight loss telehealth membership by the end of the month, it announced last week along with

23 and me To Enter The Weight Loss Market Read More »

Eli Lilly Posts Strong Weight Loss Drug Sales

News / John LaRosa

August 8, 2024 A Financial Times article reported that… “Eli Lilly chief executive David Ricks said the better than expected sales in its most recent quarter were driven by the GLP-1 medicines as the drugmaker “advanced our manufacturing expansion agenda” to meet the huge demand for the medicines. Increased pricing power for Mounjaro also boosted

Eli Lilly Posts Strong Weight Loss Drug Sales Read More »

Medifast Reports Q2 Results

News / John LaRosa

August 5, 2024 Wellness company Medifast (NYSE:MED) fell short of analysts’ expectations. Management said that: “We are acting decisively to transform our business to position us for long-term growth, with a strong balance sheet free of debt, a clear focus on new customer acquisition, and a broader health and wellness offer to a significantly expanded

Medifast Reports Q2 Results Read More »

Hims & Hers To Offer Certificates of Analysis for Compounded GLP-1s

News / John LaRosa

August 1, 2024 In August, Certificates of Analysis on the compounded GLP-1 medications available through Hims & Hers will be accessible to customers, in an effort to introduce a higher level of transparency that helps our customers understand what is in the medications they receive, as well as how to understand the high quality standards

Hims & Hers To Offer Certificates of Analysis for Compounded GLP-1s Read More »

Nearly all patients quit weight loss shots within two years, study finds

News / John LaRosa

July 11, 2024 An article by Endpoints.com cited a study that found that only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years, according to a new analysis by pharmacy benefit manager Prime Therapeutics. Prime, which is owned by a group of Blue Cross Blue Shield

Nearly all patients quit weight loss shots within two years, study finds Read More »

Employers and Insurers Push Back on GLP-1 Drugs Coverage

News / John LaRosa

June 13, 2024 Just 33% of employers and health plans cover the drugs for obesity, according to a report published Tuesday by consultant firm Pharmaceutical Strategies Group. The biggest reason? The drugs’ high costs. “Affordability is the main challenge, and we have seen a few employers offer coverage, then pull back after they evaluated the

Employers and Insurers Push Back on GLP-1 Drugs Coverage Read More »